A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration

Inclusion Criteria: Subfoveal choroidal neovascularization (CNV) due to AMD

Exclusion Criteria:

• Any of the following underlying diseases including:
• Diabetic retinopathy.
• History or evidence of severe cardiac disease (e.g., NYHA Functional Class III orIV - see Appendix 19.6), history or clinical evidence of unstable angina, acutecoronary syndrome, myocardial infarction or revascularization with 6 months,ventricular tachyarrythmias requiring ongoing treatment.
• History or evidence of clinically significant peripheral vascular disease, suchas intermittent claudication or prior amputation.
• Clinically significant impaired renal (serum creatinine >2.5 mg/dl or s/p renaltransplant or receiving dialysis) or hepatic function.
• Stroke (within 12 months of trial entry).
• Any major surgical procedure within one month of trial entry. Previoustherapeutic radiation in the region of the study eye. Any treatment with aninvestigational agent in the past 60 days for any condition. Known serious allergies to the fluorescein dye used in angiography, to the components ofthe ranibizumab formulation, or to the components of the E10030 formulation.